@Budge - The migration to and formulation of the drugs for the SubQ market is in its early stages. The proving of a an acceptable safety profile is more a confirmation of what seems obvious. Other studies have shown that the administering of drugs via SubQ results in a more even drug level within the patients. Less spikes and valleys and hopefully less negative side effects.
News 
Market Data 
Discover 
